June 24, 2023
Announced at the EASL Congress 2023, steatotic liver disease (SLD) is selected as the overarching term for the aetiologies of steatosis. Nonalcoholic fatty liver disease (NAFLD) is now defined as metabolic dysfunction-associated steatotic liver disease (MASLD), and nonalcoholic steatohepatitis (NASH) is now defined as metabolic dysfunction-associated steatohepatitis (MASH).
This change in terminology reflects the importance of addressing the underlying metabolic factors that contribute to MASLD and MASH and the importance of diagnosis based on affirmative rather than exclusionary criteria.
As clinical research experts focused on the continuum of metabolic diseases, ProSciento recognizes the significance of these changes. We are committed to supporting further advances in MASLD and MASH scientific research, therapeutic development, and biomarker discovery.
Additional details about the new nomenclatures are available in the multinational liver societies’ websites:
